Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease within 16 weeks prior to Screening~* Mean Screening hemoglobin between 8.0 and \<11.0 grams per deciliter (g/dL) (inclusive)~* Serum ferritin ≥100 nanograms per deciliter (ng/mL) and TSAT ≥20% during Screening~Exclusion Criteria:~* Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss~* Red blood cells transfusion within 8 weeks prior to randomization~* Anticipated to recover adequate kidney function to no longer require dialysis~* Uncontrolled hypertension~* Severe heart failure at Screening (New York Heart Association Class IV)~* Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction); surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity); surgical or percutaneous valvular replacement or repair; sustained ventricular tachycardia; hospitalization for congestive heart failure; or stroke within 12 weeks prior to or during Screening.~* Participants meeting the criteria of erythropoiesis-stimulating agent resistance within 8 weeks prior to or during Screening defined as follows~  1. epoetin: \> 7700 units/dose three times per week or \>23,000 units per week~ 2. Darbepoetin alfa: \>100 micrograms per week (mcg/week)~ 3. methoxy polyethylene glycol-epoetin beta: \>100 micrograms (mcg) every other week or \>200 mcg/month~* Hypersensitivity to Vadadustat, Darbepoetin alfa or any of their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat (Type: EXPERIMENTAL): None
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).